Next, we assessed C-Raf, B-Raf, Akt expression and phosphorylation levels in tumor and normal tissues from ER/PR + Her2- (Fig. 3a), ER/PR + Her2+ (Fig. 3b), ER/PR-Her2+ (Fig. 3c) and ER/PR-HER2- (Fig. 3d) breast cancer patients by immunoblot analysis. This evidence concerns the gene ERBB2 and neoplasm.